In terms of treatment, Clingen enables the development of targeted therapies that specifically attack cancer cells based on their genetic mutations. This approach minimizes damage to healthy cells and reduces side effects. For example, drugs like Imatinib are designed to target the BCR-ABL fusion gene in chronic myeloid leukemia (CML), offering more effective treatment outcomes.